Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Feng Jiao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5159687038. Sources: OpenAlex.

Their work

Papers
28 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2014: 2 papers · 2015: 3 papers · 2016: 5 papers · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: 4 papers · 2021: 3 papers · 2022: 3 papers

Papers 28

  1. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Co-author DOI 10.1002/cac2.12238↗
  2. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.103897↗
  3. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. First author DOI 10.1016/j.jncc.2022.08.006↗
  4. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Co-author DOI 10.1038/s41421-021-00271-4↗
  5. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08375-6↗
  6. A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer. Co-author DOI 10.21037/tcr-20-3478↗
  7. RNA-binding protein Musashi2 regulates Hippo signaling via SAV1 and MOB1 in pancreatic cancer. Co-author DOI 10.1007/s12032-020-01384-8↗
  8. Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer. Co-author DOI 10.1186/s12935-020-1135-0↗
  9. Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. Co-author DOI 10.1186/s13046-019-1489-0↗
  10. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma. Last author DOI 10.20892/j.issn.2095-3941.2019.0427↗
  11. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis. Co-author DOI 10.1158/1541-7786.mcr-18-0910↗
  12. JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1/2-MMP-2/9 signaling pathway both in vitro and in vivo. Co-author PMID 30899402↗
  13. A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of po… Co-author DOI 10.1186/s12885-018-4954-9↗
  14. Synergistic effects of the combination of 5-Aza‑CdR and suberoylanilide hydroxamic acid on the anticancer property of pancreatic cancer. Co-author DOI 10.3892/or.2017.6059↗
  15. A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.23984↗
  16. Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. Co-author DOI 10.1038/s41598-017-00288-4↗
  17. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancrea… Co-author DOI 10.18632/oncotarget.14069↗
  18. Correlated high expression of FXR and Sp1 in cancer cells confers a poor prognosis for pancreatic cancer: A study based on TCGA and tissue microarray. Co-author DOI 10.18632/oncotarget.16633↗
  19. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Co-author DOI 10.1007/s13277-015-4741-z↗
  20. EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic ca… First author DOI 10.18632/oncotarget.7156↗
  21. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.7663↗
  22. Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.8593↗
  23. Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer. Co-author DOI 10.2174/1566524016666160927095812↗
  24. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype. Co-author DOI 10.1007/s12032-015-0589-8↗
  25. Functional significance of macrophages in pancreatic cancer biology. First author DOI 10.1007/s13277-015-4127-2↗
  26. Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Co-author DOI 10.3390/ijms16046677↗
  27. Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax. Co-author DOI 10.3892/ijo.2014.2568↗
  28. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Co-author DOI 10.3892/or.2014.3518↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiujie Cui · 17 shared papers, 2015–2022 · strength 1.69
  2. Ting Han · 14 shared papers, 2015–2021 · strength 1.21
  3. Liwei Wang · 10 shared papers, 2014–2022 · strength 0.98
  4. Meng Zhuo · 11 shared papers, 2016–2020 · strength 0.96
  5. Hai Xia Hu · 11 shared papers, 2014–2019 · strength 0.77
  6. Haiyan Yang · 6 shared papers, 2016–2021 · strength 0.62
  7. Liwei Wang · 9 shared papers, 2014–2017 · strength 0.57
  8. Tiebo Mao · 5 shared papers, 2021–2022 · strength 0.56
  9. Jiong Hu · 5 shared papers, 2020–2022 · strength 0.55
  10. Liwei Wang · 5 shared papers, 2018–2022 · strength 0.51
  11. Jiayu Yao · 4 shared papers, 2021–2022 · strength 0.45
  12. Yongwei Sun · 4 shared papers, 2021–2022 · strength 0.41
  13. Deliang Fu · 4 shared papers, 2021–2022 · strength 0.41
  14. Ming Quan · 4 shared papers, 2015–2020 · strength 0.37
  15. Yiyi Liang · 3 shared papers, 2020–2021 · strength 0.35
  16. Yu Wang · 3 shared papers, 2021–2022 · strength 0.32
  17. Xiaofei Zhang · 3 shared papers, 2021–2022 · strength 0.32
  18. Lei Wang · 4 shared papers, 2014–2017 · strength 0.25
  19. Liwei Wang · 2 shared papers, 2018–2020 · strength 0.22
  20. Yingbin Liu · 2 shared papers, 2022 · strength 0.22
  21. Yuexiang Wang · 2 shared papers, 2022 · strength 0.22
  22. Yu Wang · 2 shared papers, 2017–2022 · strength 0.19
  23. Leilei Wu · 2 shared papers, 2017 · strength 0.14
  24. Junjie Hang · 2 shared papers, 2016 · strength 0.13
  25. Qiang Liu · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.